Non-Alcoholic Steatohepatitis (NASH) Market Outlook: 2024-2028

The non-alcoholic steatohepatitis market is projected to experience significant growth, with a forecasted increase of USD 31.46 billion at a compound annual growth rate (CAGR) of 58.37% between 2023 and 2028. This growth is driven by rising obesity and metabolic syndrome prevalence, coupled with the absence of approved therapies for NASH, which opens opportunities for innovative treatments and interventions. Increasing awareness, patient engagement, and education are key trends in the market, as individuals become more informed about the disease’s risks and symptoms.

For more details about the industry, get the PDF sample report for free

Key Market Segments:

1. Distribution Channels:

   • Offline: The offline segment is poised for substantial growth, especially in the distribution of diagnostic tools and educational resources. Healthcare providers and clinics play a significant role in spreading awareness and offering diagnostic tests, contributing to the growth of offline distribution channels.
   • Online: The online segment is also witnessing rapid expansion due to telemedicine and online consultations increasing access to diagnosis and treatment options.

2. Applications:

   • Diagnosis: Diagnostic tools like liver biopsies, blood tests, and ultrasound are crucial for identifying NASH. Companies like Akero Therapeutics and Boehringer Ingelheim are investing in diagnostic advancements.
   • Treatment: Pharmaceutical companies are exploring therapies, with candidates like Genfit’s elafibranor and Akeros Therapeutics’ AKR-001 in development.

Regional Insights

1. North America: North America is expected to contribute 51% of the market’s growth during the forecast period. The high prevalence of risk factors such as obesity and metabolic syndrome in the U.S. significantly drives the market. Companies such as Intercept Pharmaceuticals and Genfit are at the forefront of developing therapies. In the U.S., the CDC reports that over 80 million Americans are affected by insulin resistance, a major risk factor for NASH.

2. Europe: In Europe, countries like Germany and the UK are seeing increasing cases of NASH due to high obesity rates. Companies like Novo Nordisk and Siemens Healthineers are making strides in diagnostics and treatment development.

3. Asia: Countries like China are witnessing a rise in NASH prevalence due to urbanization and dietary shifts leading to higher rates of obesity and metabolic syndrome.

4. Rest of World (ROW): In other regions, the growing adoption of advanced diagnostics and treatments will continue to increase the global footprint of the NASH market.

Key Market Drivers:

1. Rising Prevalence of Obesity and Metabolic Syndrome: NASH is closely linked to obesity, insulin resistance, and metabolic syndrome, which are increasingly common in the U.S. Obesity alone contributes significantly to NASH development, as evidenced by more than one-third of U.S. adults being obese (CDC). This trend is a major driver behind the surge in NASH cases and the demand for effective treatment options.

2. Lack of Approved Therapies: The absence of FDA-approved therapies for NASH has created a gap in the market, pushing pharmaceutical companies to invest heavily in clinical trials and treatment development.

3. Increasing Awareness and Education: There is a growing trend of patient engagement, with more individuals learning about NASH’s risks and the importance of early diagnosis and lifestyle changes. This trend is helping manage the condition before it leads to severe liver damage or liver transplants.

Market Trends:

1. Patient Engagement and Education: As awareness about NASH increases, there is a significant rise in patient education programs. These initiatives are critical in helping individuals make lifestyle changes, such as weight loss and dietary modifications, which are essential for managing NASH effectively.

2. Diagnostic Advancements: Non-invasive diagnostic techniques, such as transient elastography, are gaining popularity due to their accuracy and minimal invasiveness, aiding in early NASH detection.

Market Challenges:

1. Lack of Approved Therapies: The absence of FDA-approved treatments remains a significant challenge. This not only affects disease management but also increases healthcare costs and the risk of complications, including cirrhosis and cardiovascular diseases.

2. Need for Effective Lifestyle Modifications: Despite the recognition of NASH, effective lifestyle changes (weight management and exercise) are crucial yet difficult for many patients to maintain consistently.

Get more details by ordering the complete report

Key Companies in the Non-Alcoholic Steatohepatitis (NASH) Market

Some of the key companies of the Non-Alcoholic Steatohepatitis (NASH) Market are as follows:

• AstraZeneca Plc
• BioPredictive S.A.S
• Cirius Therapeutics
• Enzo Biochem Inc.
• GENFIT SA
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Intercept Pharmaceuticals Inc.
• Inventiva S.A.
• Madrigal Pharmaceuticals Inc.
• Novo Nordisk AS
• Prometheus Laboratories
• Siemens Healthineers AG
• Zydus Lifesciences Ltd.

Recent Market Developments:

1. January 2024: Genfit announced a promising update on its clinical trials involving elafibranor, with encouraging results in reducing liver fibrosis in NASH patients.

2. December 2023: Intercept Pharmaceuticals received FDA approval for its investigational treatment for NASH, marking a milestone in the treatment landscape.

3. November 2023: Boehringer Ingelheim launched a major phase 3 trial for a new antidiabetic agent aimed at addressing metabolic factors associated with NASH.